Navigation Links
BioReliance Launches Next-Generation Genotoxicity Screening Service
Date:9/12/2007

ROCKVILLE, Md., Sept. 12 /PRNewswire/ -- BioReliance Corporation, a leading contract services organization for the biopharmaceutical and pharmaceutical industries, has contracted with Gentronix to offer their GreenScreen HC in vitro assay as a major part of BioReliance's portfolio of genotoxicity screening services. GreenScreen HC, in conjunction with Ames II assays, allows pharmaceutical companies to test for genotoxic potential earlier in the preclinical development process, using only a few milligrams of test compound as opposed to the gram quantities required by current ICH regulatory tests.

John Nicholson, Chairman and CEO of Gentronix, comments, "We are delighted to complete this agreement with BioReliance, a company regarded as a global leader in genetic toxicology testing services." "This new high-throughput assay from Gentronix furthers BioReliance's ability to meet customer demand for faster and more effective genotoxic screening services," adds David Bruning, Senior Director, Toxicology Operations at BioReliance. "The GreenScreen HC and Ames II assays, when combined, offer highly predictive and sensitive detection of genotoxic compounds while minimizing false positives seen with other in vitro assays, accelerating the development process."

GreenScreen HC is a unique human cell-based genotoxicity screening assay that links the regulation of the human Growth Arrest and DNA Damage (GADD45a) gene to the production of Green Fluorescent Protein (GFP). Cells that have incurred DNA damage upon exposure to a test compound express higher levels of detectable GFP.

GreenScreen HC only requires 1 mg of starting material to demonstrate high specificity, in contrast to other in vitro genetic toxicology assays that often provide false positive results. GreenScreen HC is able to detect multiple mechanistic classes of genotoxic agents, including aneugens, and is easily adapted to automatic robotic platforms.

About Gentronix

Gentronix is an innovative biotechnology company helping to accelerate the pace of drug development in the pharmaceutical industry. Gentronix is developing a range of productivity-enhancing tools for scientists in the drug discovery field, designed to ease or remove current bottlenecks in preclinical research and development. Gentronix's first product release, GreenScreen, successfully combines expertise in molecular biology and analytical science to address the ADMET bottleneck in lead candidate selection, focusing specifically on genotoxicity screening. GreenScreen products are for use in genetic toxicity screening and can contribute to the selection of lead collections enriched with compounds lacking genotoxicity. For more information, visit http://www.gentronix.co.uk .

Contact

Peter McCulloch

Director, Business Development

peter.mcculloch@gentronix.co.uk

+44 161 606 7268

About BioReliance

BioReliance Corporation is a leading contract services organization, offering more than 1,000 tests or services related to biologics safety testing, in vitro and in vivo toxicology, viral manufacturing and lab animal health diagnostics for the biopharmaceutical and pharmaceutical industries. The Company provides cost-effective services to over 600 clients annually, including most of the largest pharmaceutical and biopharmaceutical companies in the world. BioReliance is headquartered in Rockville, Maryland and has additional facilities in Glasgow, Scotland and Stirling, Scotland. For more information, visit http://www.bioreliance.com .

Contact

David Bruning

Senior Director, Business Operations, Toxicology and LADS

david.bruning@bioreliance.com

+1 301.610.2653


'/>"/>
SOURCE BioReliance Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Merge launches diagnostic mammography workstation in Europe
2. Einstein Wireless launches cellular alert system
3. Logistics Health launches compliance management tool
4. UW-Madison launches new high-speed research network
5. UWM launches research foundation
6. TeraMedica launches information manager
7. GE Healthcare launches hybrid electronic record
8. Cedara launches new version of DICOM toolkit
9. Merge launches Spanish version of imaging tool
10. Doyle launches 2025 alternative energy plan
11. Jellyfish launches comparative shopping website
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... ... May 23, 2017 , ... Customers often prefer ... again and again. METTLER TOLEDO has released two new videos that show how ... integration of the ACT350 into Siemens and Allen Bradley PLCs is easy and ...
(Date:5/21/2017)... (PRWEB) , ... May 19, 2017 , ... ... meeting and educational conference of the American Association of Bioanalysts (AAB) and the ... Hotel in Houston. The conference reinforces AAB’s commitment to excellence in clinical laboratory ...
(Date:5/18/2017)... Mass. (PRWEB) , ... May 18, 2017 , ... ... the procedure on April 28, 2017 at the Prince Of Wales Private Hospital. ... cervical disc at level C6-C7. The patient failed conservative treatments prior to undergoing ...
(Date:5/18/2017)... , ... May 17, 2017 ... ... standards with psychonneuroendocrine stress expertise, and further enhances its scientific power by ... Douglas A. Granger, Ph.D., has agreed to join the scientific advisory board. ...
Breaking Biology Technology:
(Date:5/16/2017)... May 16, 2017  Veratad Technologies, LLC ( www.veratad.com ... age and identity verification solutions, announced today they will ... 2017, May 15 thru May 17, 2017, in ... International Trade Center. Identity impacts the ... in today,s quickly evolving digital world, defining identity is ...
(Date:4/18/2017)... April 18, 2017  Socionext Inc., a global expert in SoC-based ... edge server, the M820, which features the company,s hybrid codec technology. ... by Tera Probe, Inc., will be showcased during the upcoming Medtec ... show at the Las Vegas Convention Center ... Click here ...
(Date:4/11/2017)... Research and Markets has announced the addition of the ... ... to grow at a CAGR of 30.37% during the period 2017-2021. ... been prepared based on an in-depth market analysis with inputs from ... prospects over the coming years. The report also includes a discussion ...
Breaking Biology News(10 mins):